In vivo models of cardiac diseases: Application to drug development and screening

Hirofumi Rokutan, Stefan D. Anker, Jochen Springer

Research output: Contribution to journalArticlepeer-review


Cardiac disease is the top cause of human mortality in the Western world. Current drug therapy for cardiac disease has been established via experimental studies using a variety of in vivo animal models. The purpose of this review is to discuss the features (advantages and limitations) of the mainly used in vivo models of cardiac disease and provide the reader with an overview of how they can be utilized in the development and screening of cardiac drugs. A search for articles focusing on and including in vivo models for the main areas of cardiac diseases was performed on PubMed. We also searched the reference lists of identified articles for further original articles. Large and small animal models including genetically modified ones have made accomplishments in the process of cardiac drug development with different clinical relevance. However, there is still a clear need for lessening the gap between human and experimental models by improving in vivo models.

Original languageEnglish
Pages (from-to)65-78
Number of pages14
JournalExpert Opinion on Drug Discovery
Issue number1
Publication statusPublished - Jan 2010


  • Animal model
  • Cardiac disease
  • Cardiovascular disease
  • Drug screening
  • Experimental model
  • Genetic model
  • In vivo
  • Preclinical research

ASJC Scopus subject areas

  • Drug Discovery


Dive into the research topics of 'In vivo models of cardiac diseases: Application to drug development and screening'. Together they form a unique fingerprint.

Cite this